Femasys Inc. FEMY shares are trading higher Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.
The Details:
HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday.
Shares of FEMY are up on very heavy trading volume. According to data from Benzinga Pro, more than 66 million shares have already been traded on Friday, far exceeding the stock's 100-day average of 7.256 million shares.
Femasys Inc. is a biomedical company focused on developing solutions and advancements in women's healthcare that address underserved areas.
Related News: What's Going On With T2 Biosystems Stock Friday?
FEMY Price Action: According to Benzinga Pro, FEMY shares are up 77% at $2.69 at the time of publication.
Image: Chen from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
